Get started
Work

Streamlining Daptomycin Therapy in an Academic Medical Center

Year: 2016
Type: article
Study design: Observational Study
Abstract: Background. Emerging resistance and treatment failure associated with vancomycin for methicillin-resistant S. aureus (MRSA) and other resistant Gram-positive organism such as vancomycin-resistant enterococcus (VRE) have led to increased use of daptomycin (DAP). Higher doses of DAP are increasingly selected, further escalating drug costs. Our DAP use is limited to patients with treatment failure, in vitro resistance, or vancomycin intolerance and requires antimicrobial stewardship pharmacist (ASP) review and infectious diseases consultation. The purpose of this review is to evaluate DAP use and the impact of ASP intervention on streamlining of DAP therapy. Methods. All adult inpatients who received ≥24 hours of DAP between 1 October 2015 and 30 April 2016 were included. Patient demographics, DAP indication, dose, frequency, length of therapy, microbiological etiology and infection type, vancomycin minimum inhibitory concentration (MIC), DAP MIC, antibiotic therapy prior to DAP, and the appropriateness of DAP usage were evaluated. Data were analyzed by using descriptive statistics. Results. A total of 75 patients (median age of 64 years) were included and 23% were hemodialysis patients. Bacteremia occurred in 51% of patients. The most common sites of infections were skin soft tissue (17%) and osteoarticular (15%). Most common pathogens isolated were VRE (32%) and MRSA (23%). Majority of patients (91%) had appropriate indications for DAP therapy, most frequently for documented resistance (20%) and vancomycin allergy/intolerance (17%). DAP was initiated as empiric therapy in 35% and definitive therapy in 65% of patients. Furthermore, 35% patients were switched from DAP to alternative agents (ampicillin, vancomycin, linezolid, etc.). Median weight-based dosing (mg/kg) for Enterococcal and Staphylococcal bacteremia (IQR) were 7.0 (5.9 to 8.1) and 8.0 (7.4 to 8.7), respectively. Conclusion. DAP therapy was prescribed based on appropriate indications in >90% of patients. ASP demonstrated a positive impact on streamlining 35% of patients to appropriate therapy. With 35% of patients on empiric DAP therapy, there are opportunities for ASP to de-escalate and optimize use. Disclosures. All authors: No reported disclosures.
DOI: 10.1093/ofid/ofw172.710
Language: English
Open Access status: gold
Estimated APC paid: $4,053
OpenAlex ID: W2553793473
FWCI:
Cites:
Cited by:
Related to: 10